Kazia Presents Interim Paxalisib Phase II Data at ASCO Showing...
SYDNEY, June 1, 2020 /PRNewswire-AsiaNet/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share a poster presentation of interim data from the ongoing phase II study of paxalisib (formerly GDC-0084) in glioblastoma, ...
Authors: LATEST ASIANET NEWS RELEASES